Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015691 · ClinicalTrials.gov registry record · NA

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
105
Enrollment target

NCT00015691: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00015691 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 105 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015691, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
105 participants
Enrollment target

Study Summary

The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body. Studies have shown that certain anti-HIV medications can cause a number of side effects, including high blood sugar (resulting from the body's failure to use insulin), high insulin, and excess fat build-up in the abdominal area. These side effects are known to increase the risk of heart disease. Metformin and rosiglitazone are 2 drugs that have been shown to lower insulin resistance and lessen abdominal fat in patients who are not HIV-infected. This study will investigate the use of these drugs in HIV-infected patients.

Interventions

  • DRUG Metformin hydrochloride
  • DRUG Rosiglitazone maleate

Trial Details

FieldValue
Enrollment Target 105 participants
Phase NA

What the finished NCT00015691 record still lists

NCT00015691 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Metformin hydrochloride is the first listed.

NCT00015691 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00015691 about?

NCT00015691 is a clinical study titled "Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities". The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body. Studies have shown that certain anti-HIV medications can cause a number of sid...

What is the current status of trial NCT00015691?

This trial is currently completed. It is a NA study. The enrollment target is 105 participants.

What interventions are being tested in trial NCT00015691?

The interventions under investigation include: Metformin hydrochloride (DRUG), Rosiglitazone maleate (DRUG).

Who is sponsoring clinical trial NCT00015691?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00015691's enrollment target sits among peer trials

105 834th of 2000 higher than 1,165 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Source: ClinicalTrials.gov NCT00015691, the US trial registry maintained by the National Library of Medicine. NCT00015691 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.